Corrected: FDA pushes back review of GlaxoSmithKline treatment for restless leg syndrome
GSK's HQ in London
On The Web
Site Search
Get the latest news alerts: Follow LTW at Twitter.
Local Tech Wire
Editor's note: XenoPort issued a correction to a press release issued last Friday about the FDA delay in review of a proposed drug. Rather than a treatment for shingles, XenoPort said the drug involved is for restless leg syndrome.
"The NDA currently under review by the FDA is for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS). The original PDUFA date for this NDA review was November 9, 2009," XenoPort said.
RESEARCH TRIANGLE PARK, N.C. – The U.S. Food and Drug Administration has pushed back its delay of a proposed treatment for restless leg syndrome that is being developed by GlaxoSmithKline (NYSE: GSK) and California-based XenoPort.
The companies announced the FDA’s decision after markets closed on Friday.
The FDA had been expected to announce a decision on the new drug application filed by GSK and XenoPort on Nov. 9. Instead, the FDA requested additional data and pushed back the review date to Feb. 9, 2010.
GSK maintains its U.S. headquarters in RTP and employs some 4,000 people in the area.
Copyright 2012 WRAL Tech Wire. All rights reserved.
Featured
E-mail Preferences
The Skinny
- What brands are winning Super Bowl hype? Two Durham firms to find out
- In Super Bowl of social media, Patriots win, Triangle firm says
- Big job cuts coming at IBM? Don't be surprised
- Erskine Bowles is among those who can cash in big time on Facebook IPO
- Ignore Facebook hype - Check out 'risk factors,' too
- Facebook vs. Google IPO: Which deal ranks better?
- Triangle StartUp Factory says business already booming
- Entrepreneurship remains at heart of Tech Wire mission
- Flashback: Tech Wire launched 10 years ago today
- Silicon Valley's 'most provocative voice' - Former RTP exec Vivek Wadhwa